68
Participants
Start Date
January 31, 2009
Primary Completion Date
October 31, 2009
Study Completion Date
May 31, 2013
Radiation therapy
Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
Temozolomide
Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
Bevacizumab
Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
Bevacizumab
Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
Everolimus
Everolimus 10mg by mouth daily, beginning Week 11
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
Peninsula Cancer Institute, Newport News
South Carolina Oncology Associates, PA, Columbia
Northeast Georgia Medical Center, Gainesville
Florida Cancer Specialists, Fort Myers
Clearview Cancer Institute, Huntsville
Tennessee Oncology, PLLC, Nashville
Consultants in Blood Disorders and Cancer, Louisville
Grand Rapids Clinical Oncology Program, Grand Rapids
St. Louis Cancer Care, Chesterfield
Research Medical Center, Kansas City
Methodist Cancer Center, Omaha
Collaborators (2)
Genentech, Inc.
INDUSTRY
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER